Background: Patients with chronic kidney disease (CKD) experience much more marked and earlier muscle wasting than subjects who do not have chronic illnesses.
Statistical analysis
The categorical variables were recorded as numbers and percentages. The continuous variables are presented as the mean ± standard variation or median (IQR).
Student's t-tests, Mann-Whitney U tests or ANOVAs were used to compare the continuous variables. The categorical variables were compared using χ2 tests or Fisher's exact tests. Pearson's correlation coefficients were used to summarize the cross-sectional relationships among age, hand grip strength, HOMA-IR, and ASM.
Kaplan-Meier curves were used to estimate event times, and the distributions were compared via log-rank tests. A Cox regression model was used to analyze the independent variables that were associated with hospitalization or mortality. A p-value < 0.05 was considered to be statistically significant. Statistical analyses were performed using SPSS for Windows (version 21; SPSS, Chicago, IL, USA). Table 1 shows the baseline clinical and biochemical characteristics of the study population. The mean age was 60.6 ± 13.5 years old. Of the patients in this study, 63.6% were male, and 44.7% had diabetes. The mean estimated glomerular filtration rate was 39.2 ± 20.4 ml/min/1.73 m 2 among the predialysis patients. Of the predialysis patients, 28.9% were classified as Stage 3a, 30.1% were classified as Stage 3b, 24.1% were classified as Stage 4, and 16.9% were classified as Stage 5. Chronic hemodialysis patients (Stage 5D) comprised 42.5% of the patients in this study, and their mean duration of dialysis was 52.9 ± 47.7 months. The mean Kt/V of the chronic hemodialysis patients was 1.7 ± 0.3. 
Results

Study population
Prevalence of sarcopenia and associated factors
Based on the 3 different indices (ASM/wt, ASM/ht 2 and ASM/BMI; The analysis via the use of Pearson's correlation coefficients revealed that the absolute value of ASM was negatively correlated with age (r = -0.432, p < 0.001) and frailty scores (r = -0.330, p < 0.001) but positively correlated with grip strength (r = 0.607, p < 0.001, Figure 1 ). The ASM/wt index had inverse correlations with age (r = -0.247, p = 0.009), HOMA-IR (r = -0.202, p = 0.015) and frailty scores (r = -0.291, p < 0.001) and had a positive correlation with handgrip strength (r = 0.371, p = 0.009) ( Figure 1 ). The ASM/Ht 2 index was only modestly correlated with handgrip strength (r = 0.239, p = 0.002) and frailty scores (r = -0.261, p = 0.004). However, the ASM/BMI index showed no significant relationships with age, handgrip strength, HOMA-IR or frailty scores ( Figure 1 ). 
Characteristics based on sarcopenia status categorized by the ASM/wt index
The ASM/wt index showed the best correlations with chronological age, muscle strength, insulin resistance and geriatric syndrome, which suggests that the ASM/wt index might be the most appropriate and practical index in our subjects. In view of this contention, we divided our subjects into normal, presarcopenia, or sarcopenia groups, based on the ASM/wt index (Table 3) .
The patients with presarcopenia were older than the normal patients, and the patients with sarcopenia were much older than the patients with presarcopenia (p < 0.001).
More diabetic patients were included in the groups of presarcopenia and sarcopenia patients than were included in the normal patient group (p = 0.014). Handgrip strength and walking speed gradually decreased in the patients with presarcopenia and sarcopenia compared with those in the patients with normal skeletal muscle mass and function (p < 0.001). HOMA-IR was significantly and progressively increased in the presarcopenia and sarcopenia patients (p = 0.041), which indicates that they may have metabolic problems compared to those patients in the normal group. The patients with sarcopenia had relatively lower hemoglobin, albumin, calcium and 25(OH)D levels, but they were not statistically significantly lower. Sarcopenic patients had trends for higher phosphate, iPTH, and CRP levels, but these trends were not statistically significant. The hospitalization-free survival, according to the sarcopenia status in patients with CKD, is shown in Figure 2 . The Kaplan-Meier analysis revealed that the risk of hospitalization was gradually increased in presarcopenic and sarcopenic patients, compared to that in the normal group (log-rank test: p < 0.001). In the univariate Cox proportional analysis, age, the administration or lack of dialysis, the presence of cardiac disease, serum albumin levels, serum creatinine levels and sarcopenia were significant predictors of all-cause hospitalizations in CKD patients ( Table 5 ). was associated with CKD stage in men (32) . In a study that utilized a recent definition of sarcopenia, which was represented by the simultaneous incidence of low muscle mass and decreased power, the prevalence of sarcopenia was 5.9-9.8%, depending on the muscle mass assessment method used in the predialysis CKD patients (33) .
Sarcopenia and Clinical Outcomes
Lamarca et al. investigated sarcopenia in elderly maintenance hemodialysis patients
and found that the prevalence of muscle weakness that was measured by handgrips was 85%, but the prevalence of decreased muscle mass varied from 4-73.5%, depending on the method that was used and the cutoff value that was applied (34) .
One of the challenges in studies of sarcopenia is to determine how best to measure the amount of muscle. However, the European Working Group on Sarcopenia in Older People, as well as the AWGS, recently established a clear criterion for the diagnosis of sarcopenia (35, 36) . The guideline recommends the use of a bioimpedence analysis, dual-energy X-ray absorptiometry, computed tomography, and magnetic resonance imaging to measure the skeletal muscle mass. Bioimpedance analysis, which was used in our study, is a popular method for estimating body composition and has the merits of being low-cost, easy-to-use and portable. Furthermore, the bioimpedance analysis results, under standard conditions, have been found to correlate well with MRI predictions, and the prediction equations have been validated for various populations (37) . In our data, the combined prevalence of sarcopenia and presarcopenia, through the use of adjusted ASM that was measured by bioimpedance analysis, was approximately 60% (Table 2 ). Finally, approximately 40% of the subjects had normal muscle mass and strength. Our data showed that muscle failure is common in CKD patients, which is consistent with other epidemiologic studies of sarcopenia or low muscle mass in that population (11) (12) (13) . In comparison with the results from healthy Korean women who were older than 65 years old, 21% of them were classified into either presarcopenia or sarcopenia groups (38) .
Sarcopenia does not involve only muscle mass or strength but also involves basal metabolic rates (39) . Muscles are the largest repository of protein, the most important site for the storage of glucose and the major critical consumer of energy. Thus, sarcopenia contributes to decreased energy demands of the human body (39) . Of course, sarcopenia, including reduced muscle mass, has negative consequences for human health. Muscle weakness, which is one component of sarcopenia, has been reported to be associated with poor health outcomes, such as mortality, hospitalization, and disabilities in predialysis and dialysis patients (40) . Pereira et al. suggested that predialysis patients with sarcopenia had higher mortality rates (33) . In our study, both sarcopenia and presarcopenia were predictive of hospitalization-free survival among CKD outpatients, including patients in the predialysis and dialysis stages ( Figure 2 ).
Exercise interventions could be the primary treatment options for sarcopenia. Indeed, most exercise trials have shown improved muscle strength, physical performance and muscle mass in community-dwelling, elderly individuals, although these individuals were not recruited based on their sarcopenic status (41) (42) (43) (44) . Additionally, essential amino acid and β-hydroxy β-methylbutyric acid (HMB, which is a bioactive metabolite of leucine) supplements seem to have some effects on muscle mass and muscle function; however, these effects need to be confirmed in larger trials (45-48). Vitamin D, testosterone, or myostatin inhibitors have also been proposed as potential drugs for the treatment of muscle failure (49) (50) (51) . Remarkably, there are several studies that support the idea that exercise may enhance muscle strength in CKD patients (52) .
Howden et al. reported that 12-month exercise and lifestyle interventions improved 6-minute walk distances in patients with CKD stages ranging from 3 to 4 (53).
Greenwood et al. showed that the completion of a 12-week exercise rehabilitation regimen enhanced physical performance and reduced cardiovascular morbidity (54) .
However, the effects of exercise training on sarcopenia are unclear in patients with CKD. To confirm these effects, it is necessary to identify the prevalence of sarcopenia, according to the recently suggested definition and to examine its relationship with clinical outcomes among the CKD patient population.
There were several limitations of our study. First, this was a small, single-center study that had a relatively short observation period. However, this study had several strengths. We used a definition of sarcopenia that included the two components of low muscle mass and muscle strength. Furthermore, we used a direct physical function test to estimate muscle strength. We compared the prevalence of sarcopenia by using three different muscle indices and explored the most appropriate muscle indices in CKD patients, which may reflect their chronological age, muscle power, metabolic derangement, and frailty. Lastly, we examined whether the selected muscle index was a good predictor for clinical prognoses in our subjects.
In conclusion, our findings showed that sarcopenia and presarcopenia can be useful for predicting hospitalization in CKD outpatients. Future studies on sarcopenia may provide new methods for gaining insights into the disease and for improving their prognoses. Therefore, we should recognize the sarcopenic and presarcopenic statuses of patients as risk factors for poor clinical outcomes and proceed with further research on the relationship between these risk factors and disease status.
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